報價延遲最少15分鐘:2026/03/09 18:37 EDT
盤後時段
|
||||
|
84.2 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
84.26
|
|
|
| 價值評估 |
|
盈利(現時/預測)
1.83/3.18
|
|
企業價值
48.06B
|
| 資產負債 |
|
每股賬面淨值
17.80
|
| 現金流量 |
|
現金流量率
0.03
|
| 損益表 |
|
收益
6.07B
|
|
每股收益
10.03
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US. |
